scholarly article | Q13442814 |
P356 | DOI | 10.1159/000273461 |
P698 | PubMed publication ID | 20173364 |
P50 | author | Elisabetta Costantini | Q37829879 |
Massimo Lazzeri | Q37829898 | ||
P2093 | author name string | Luigi Mearini | |
Massimo Porena | |||
Michele Del Zingaro | |||
Vittorio Bini | |||
Antonella Giannantoni | |||
P433 | issue | 1 | |
P921 | main subject | bladder cancer | Q504775 |
P304 | page(s) | 23-27 | |
P577 | publication date | 2010-02-17 | |
P1433 | published in | Urologia Internationalis | Q26854025 |
P1476 | title | Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study | |
P478 | volume | 84 |
Q92900076 | Alternative Therapies to Bacillus Calmette-Guérin Shortage for Nonmuscle Invasive Bladder Cancer in Brazil and Other Underdeveloped Countries: Management Considerations |
Q47114392 | Alternative therapies in patients with non-muscle invasive bladder cancer |
Q37970466 | Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancer |
Q38943258 | B7-H4 expression in bladder urothelial carcinoma and immune escape mechanisms |
Q87838911 | Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with non-muscle invasive bladder cancer? An update and cumulative meta-analysis |
Q37872240 | Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy |
Q37812604 | Developments in intravesical therapy for non-muscle-invasive bladder cancer |
Q37696178 | Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis |
Q24203884 | Intravesical gemcitabine for non-muscle invasive bladder cancer |
Q37982150 | Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review |
Q37813081 | Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer. |
Q103834991 | Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure |
Q90539551 | Nonmuscle Invasive Bladder Cancer Influences Physical Health Related Quality of Life and Urinary Incontinence |
Q86507875 | Perioperative chemotherapy: when to use it, what to use, and why |
Q84060912 | Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: what does an aborted trial tell us? |
Q36141505 | Pityriasis rosea-like rash secondary to intravesical bacillus calmette-guerin immunotherapy |
Q42913625 | Re: Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance |
Q39209020 | Tackling non-muscle invasive bladder cancer in the clinic |
Q58795653 | The efficacy and safety of intravesical gemcitabine vs Bacille Calmette-Guérin for adjuvant treatment of non-muscle invasive bladder cancer: a meta-analysis |
Q54282483 | [Intravesical gemcitabine for non-muscle invasive bladder cancer]. |
Q83598879 | [New concepts in management of NMIBC in 2010] |
Search more.